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Radioactive carcinogens haveprovided mostofourpresentknowledgeaboutthechemistry ofinteractions
between carcinogens and biological systems. The requirement of radioactive carcinogens has restricted
carcinogen-DNA binding studies to chemicals that are readily available in isotopically labeled form, i.e.,
a minute fraction of all potentially mutagenic or carcinogenic chemicals. To extend the scope of carcin-
ogen-DNA binding studies, an alternative method, which does not require radioactive test chemicals, has
been developed. In this approach, radioactivity (32P) is being incorporated into DNA constituents by
polynucleotide kinase-catalyzed [3PIphosphate transfer from [y-32P]ATP after exposure of the DNA in
vitro or in vivo to a nonradioactive, covalently binding chemical, and evidence for the alteration of DNA
nucleotides is provided by the appearance of extra spots on autoradiograms of thin-layer chromatograms
of digests ofthe chemically modified DNA. Quantitation of adduct levels is accomplished by scintillation
counting. The sensitivity ofthe technique depends on the experimental conditions for 32P-labeling and on
the chemical structure ofthe adducts. Greater sensitivity may be achieved if adducts can be separated as
a class from the normal nucleotides. This is the case for an estimated 80% of all carcinogens, giving rise
to bulky and/or aromatic substituents in DNA. Under the present conditions, one such adduct in 109 to
1010 normal nucleotides can be detected. A total ofapproximately 80 compounds has been studied thus far.
Binding to DNA ofrodent tissues was readily detected by the "2P-postlabeling assay for all known carcin-
ogens among these compounds, and adducts were detected in DNA from human placenta of smokers.
Introduction
Any chemical capable offorming covalent bonds with
DNA of somatic and reproductive mammalian cells in
vivo is a potential mutagen, carcinogen, and teratogen.
Since such genotoxic chemicals may be of natural or
man-made origin, exposure to them cannot be com-
pletely eliminated, but human contact with them must
be minimized. Methods enabling one to detect and quan-
tify DNA binding potential ofchemicals directly in vivo
should be ofgreat value inthedetectionofgene-altering
chemicals in the environment, provided they can be ap-
plied to alarge numberofchemicals ofdiverse structure
and their sensitivity is sufficient to detect low DNA-
binding activities. Because covalent DNA binding of
chemicals in experimental animals may range from one
adduct in 103 normal nucleotides to one adduct in 109 to
1010 nucleotides, such methods should ideally be capable
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of detecting extremely low binding of the order of a
single adduct per diploid mammalian genome of about
1.2 x 1010 DNA nucleotides.
As pointed out by Lutz (1,2), the covalent binding
index (CBI), defined as ,umole of chemical bound per
mole of DNA nucleotide/millimole of chemical admin-
istered per kilogram body weight of animal, exhibits a
good quantitative correlation with the hepatocarcino-
genic potency ofchemicals ofdiverse structure. There-
fore, methods forthe analysis ofadducts in DNAshould
not only detect but also quantitate DNA binding. The
subject of this paper is to review our recent efforts to
develop such an ultrasensitive method involving 32p_
postlabeling of adducts (3-6) and to describe results
obtained by applying the method to a number of gen-
otoxic chemicals of diverse structure.
Materials and Methods
The sources of materials used in the 32P-postlabeling
procedure as well as safety precautions and chromato-
graphic and autoradiographic procedures have been re-RANDERATH ET AL.
Table 1. Compounds tested for DNA binding in vivo by 'P-postlabeling analysis.
DNA adducts
Compound Tissuea No.b Levelsc
Arylamines and derivatives
2-Acetylaminofluorene
4-Acetylaminofluorene
N-Hydroxy-2-acetylaminofluorene
N-Hydroxy-2-acetylaminophenanthrene
N-Hydroxy-4-acetylaminobiphenyl
N-Hydroxy-4-acetylamino-trans-stilbene
4-Aminobiphenyl
Benzidine
Azo compounds
4-Dimethylaminoazobenzene
Congo red
Evan's blue
Nitro compounds
4-Nitroquinoline-1-oxide
2,6-Dinitrotoluene
Polycyclic aromatic hydrocarbons
Benzo(a)pyrene
7,12-Dimethylbenz(a)anthracene
3-Methylcholanthrene
Benzo(e)pyrene
Benz(a)anthracene
Dibenz(a,c)anthracene
Dibenz(a,h)anthracene
Benzo(g,h,i)perylene
Chrysene
Anthracene
Pyrene
Perylene
Benzo(a)fluorene
Benzo(b)fluorene
Heterocyclic polycyclic compounds
Dibenzo(c,g)carbazole
Dibenzo(a,i)carbazole
Dibenz(a,j)acridine
Alkenylbenzenes
Safrole
Estragole
Methyleugenol
Myristicin
Dill apiol
Parsley apiol
Isosafrole
Elemicin
Anethole
Allylbenzene
Methylating agents
N,N-Dimethylnitrosamine
1,2-Dimethylhydrazine
N-Methyl-N-nitrosourea
Streptozotocin
Mycotoxins
Aflatoxin B1
Sterigmatocystin
MS
RL
RL
RL
RL
RL
RL
MS
MS
MS
MS
MS
MS
MS
MS
RL
MS
MS
MS
MS
MS
MS
MS
MS
MS
MS/ML
MS
MS
MS
MS
MS
MS
ML
ML
ML
ML
ML
ML
ML
ML
ML
ML
ML
ML
ML
ML
RL
RL
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9 +++
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2
1
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2
8
13
5
2
6
3
2
2
NDd
NDd
NDd
5
5
7
6
2
+
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+
+++
++
+++
+++
++
++
+ +
++
++
+
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4 +++
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3 +++
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2 +++
2 ++
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5 ++++
5 ++++
5 ++++
5 ++++
ge + + + +
15e + + +
aMS, mouse skin; ML, mouse liver; RL, rat liver.
bThese numbers reflect the total number of adducts detected, including those requiring very prolonged exposures for their detection.
'Total adduct levels; +, 1 adduct in > 107 nucleotides; + +, 1 adduct in 5 x 105-107 nucleotides; + + +, 1 adduct in 104-5 x 105 nucleotides;
++ + +, 1 adduct in < 104 nucleotides.
dNot detected.
'These adducts are oligonucleotides containing covalently bound carcinogen (see text).
58POSTLABELING TEST FOR CARCINOGEN-DNA ADDUCTS
ported previously (4,6). [Iy-y2P]ATP was synthesized in
the laboratory as described (4). To remove background
material from maps of aromatic carcinogen-DNA ad-
ducts, polyethyleneimine-cellulose (PEI-cellulose)thin
layers were given a final development in 0.35 M MgCl2
before autoradiography(6). Screen-intensified autora-
diography was performed at -80°C. For in vivo mod-
ification of DNA, female BALB/c or CD-1 mice (25 g)
and male Sprague-Dawley or Fischer rats (200 g) were
maintained on standard laboratory diet and water ad
libitum. A list ofchemicals used for animal treatments
is given in Table 1. For adduct detection in mouse skin
DNA, the backs of mice were shaved with clippers 3
dayspriortotreatment, whichwasperformedbytopical
application offour doses of 1.2 ,umole each of test com-
pounds in 200 ,uL ofsolvent. Compounds were dissolved
in acetone, except for azo dyes, which were dissolved
in acetone/water (7:3, v/v). The treatments were at 0,
24, 48, and 72 hr for arylamines and derivatives, azo
compounds, and nitro compounds, and at 0, 6, 30, and
54 hr for polycyclic aromatic hydrocarbons. Control mice
were given 200 pL of solvent alone. DNA was isolated
24 hr after the last treatment. For adduct detection in
mouse liver DNA, animals were given a single IP dose
(150 mg/kg) of methylating agent in 0.1 mL of 0.9%
NaCl; controlmice received 0.9% NaCl alone. DNA was
extracted 3 hr after administration. Alkenylbenzenes
were given to mice by IP injection of compound (400
mg/kg) in 0.2 mL tricaprylin, and liver DNA was iso-
lated 24 hr after treatment; control mice received tri-
caprylin alone. Dibenzo(c,g)carbazole was given SC to
female CD-1 mice at a dose of 12 mg/kg in tricaprylin.
For adduct detection in rat liver DNA, animals were
given a single IP dose oftest chemical (40 mg/kg) in 0.3
mL ofdimethyl sulfoxide; control rats received vehicle
alone. DNA was isolated 4 hr after administration.
Treatment with mycotoxins is detailed below. 32P-post-
labeling analysis ofDNA adducts was performed as de-
scribed previously (4,6) using 1 to 2 p,g of DNA for
enzymatic digestion and 0.15 to 0.3 ,ug of DNA nucleo-
tides for32P-labeling. For adduct intensification, the la-
beling reaction mixture contained 400 ,uM DNA-P and
1.7 puM [y-wP]ATP (9120 Ci/mmole), and apyrase treat-
ment (4) was omitted. For estimation of adduct levels,
spots were excised from replicate maps and counted by
Cerenkov assay. Appropriate blank areas of the chro-
matogram were also assayed and their count rates sub-
tracted from the sample count rates. In the case of
aromatic adducts, the amounts of32P-labeled digest ap-
plied to the thin-layer chromatograms were 150 to 460
,uCi for counting of adducts and 0.25 ,uCi for assaying
normal nucleotides. Calculations were done according
to the equations shown in Figure 1. Under the condi-
tions of excess ATP (4,6), the relative adduct labeling
(RAL) accurately reflects the adduct levels in the sam-
ples analyzed, a RAL value of 10' corresponding to a
DNA modification level of about 0.3 pmole of adduct/
mg of DNA.
Adduct quantitation by 32P-postlabeling assay
Relative adduct labeling (RAL)=
CpmAdduct(s)
CPmNormol nucleotides + CPMAdducts
RAL x 107 = No. of adducts in 107 total nucleotides
IIRAL = No. of totol nucleotides perodduct
0.3 (RAL x 107J = fmol odduct/pg DNA
FIGURE 1. Adduct quantitation involves determination of radioac-
tivities of adducts and normal nucleotides by Cerenkov counting
and calculation ofRAL values asindicated. Adjustments are made
for radioactive decay and dilutions ofnornal nucleotides for chro-
matography (4,6). IfCPmAdduct, << CpMNormalnucleotidest CPmAdducts iS
omitted from calculations ofthe denominator.
Results
For the 32P-postlabeling scheme to serve as a test for
the capacity of chemicals to bind to DNA, it should be
applicable to most or all covalently binding chemicals;
thus amajorquestion tobe answeredintheinitial phase
ofthedevelopment ofthemethodwaswhetheragreater
number of adducts of diverse structure was amenable
to 32P-postlabeling by T4 polynucleotide kinase-cata-
lyzed phosphorylation. We have thus far studied a total
of ca. 80 chemicals comprising arylamines and deriva-
tives, azo compounds, nitroaromatics, polycyclic aro-
matic hydrocarbons, heterocyclic polynuclear com-
pounds, alkenylbenzenes, mycotoxins, and methylating
agents. In every case, 32P-labeling ofcarcinogen-DNA
derivatives could be readily detected, indicating that
the 32P-postlabeling method can be applied to a very
large number of chemically diverse adducts. Many of
the compounds studied are listed in Table 1.
The 3 P-postlabeling procedure entails four consecu-
tive steps (Fig. 2): digestion of modified DNA to 3'-
mononucleotides; incorporation of 32p into the latter;
removal ofnormal nucleotides; and TLC separation and
autoradiography of 32P-labeled adduct nucleotides.
These compounds are [5'-32P]deoxyribonucleoside 3',5'-
0
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DMBA-adducted DNA
Micrococcal endonucleose
* spleen exonuclease
Ap+Gp+Tp+Cp+m5Cp + XIp+X2p+...
(Normal nucleotides) (Adducts)
32P lobeling
Standard conditions Adduct intensification
ty-32PlATP ("250 Ci/mmol) Ly-32P]ATP (-9000 Ci/mmol)
+ polynucleotide kinase + polynucleotide kinase
I'ATPI ' 1.2 x (INpI # tXpJ) [ATP7 <t rNpy J ixp.
rNp.7 Xp7 & 50 - 100 W tNp).* Xp7 ' 100
Ap+ Gp+ Tp+ Cp+*m5Cp + pX1p+pX2P+
Quantitative labeling | Preferential labeling
of Np and Xp of Xp over Np
<RALI>
<RAL2>
:IF
RALI RALI RALx /l07
RAL2 RAL2 adducts in 107nucleotides
FIGURE 2. "2P-postlabeling analysis of 7,12-dimethyl-
benz(a)anthracene (DMBA)-DNA or other aromatic adducts un-
der standard or adduct intensification conditions. Adducted DNA
is digested to normal (Ap, Gp, etc.) and adducted (X,p, X2p, etc.)
deoxyribonucleoside 3'-monophosphates, which are converted to
5'-3P-labeled deoxyribonucleoside 3',5'-bisphosphates by polyn-
ucleotide ldnase-catalyzed [3P]phosphate transfer from [-y-3P]ATP.
All the substrate nucleotides are quantitatively 3P-labeled in the
presence of an excess of ATP (left-hand side), while under ATP-
deficient conditions (right-hand side) the adducts are labeled to a
greater extent than are the normal nucleotides. [Np] + [Xp] =
[DNA-P] = Sum ofconcentrations of normal and adducted deox-
yribonucleoside 3'-monophosphates. RAL and <RAL> values are
calculated from the count rates ofadducts and normal nucleotides
(see Fig. 1). Individual <RAL> values are divided by experi-
mentally determined intensification factors (IF's) to obtain RAL
values.
bisphosphates (I). 32P-labeling of nucleotides may be
conducted under standard conditions (employing excess
ATP over DNA-P) or under adduct intensification
(ATP-deficient) conditions, as shown in Figure 2. The
latterconditions afford the preferential labelingofmany
aromatic carcinogen-DNA adducts, which results in a
greatly increased sensitivity ofadduct detection (7). In
addition to PEI-cellulose TLC, reversed-phase TLC on
octadecylsilane (C18) layers was found to separate the
normal nucleotides from the adduct nucleotides (6). To
remove the labeled normal nucleotides and resolve the
[32P]adducts, a four-directional (4-D) anion-exchange
PEI-cellulose TLC system was developed (Fig. 3). In
this procedure, freshly prepared labeled digest (14-18
,uCi/,L) is being applied slowly to the origin (Fig. 3,
OR) located close to the center of the thin-layer sheet
(20 x 20 cm). Development is begun immediately after
< - 12 - >
< - 20 -4
FIGURE 3. Diagram offour-directional (4-D) PEI-cellulose TLC for
the separation of3P-labeled carcinogen-DNA adducts. A What-
man 1 wick is attached to the top ofthe PEI-cellulose thin layer,
and 3P-labeled DNA digest is applied at OR. Developments in
direction 1 (Dl) and D2 are in 1.1 M LiCl and 2.5 M ammonium
formate (pH 3.5), respectively. These developments serve to re-
move 3P-labeled normal DNA nucleotides, 'Pi, and contaminants
whiletheadducts arebeingretained atorclosetoOR. Subsequent
separation ofthe adducts is conducted by development in D3 and
D4 with 3 M lithium formate, 7-8.5 M urea (pH 3.5), and 0.8 M
LiCl, 0.5 M Tris-HCl, 7-8.5 M urea (pH 8.0), respectively.
Alkenylbenzene-adducted DNA
| Micrococcal endonuclease +
spleen exonuclease
Ap+Gp+Tp+Cp+m5Cp + Xp+Yp +.....
(Normal nucleotides) (Adducts)
|32P] phosphate transfer:
[r32P] ATP + T4 polynucleotide kinase
pAp+pGp + pTp +pCp +*m5CppXp+p+.
Removal of 32P-labeled
normal nucleotides:
C18 reversed-phase TLC
pXp + pYp +.....
Contact transfer from C18 layer
to PEI-cellulose layer, then
2-dimensional anion-exchange TLC
Maps of 32P-labeled alkenylbenzene-DNA adducts
FIGURE 4. In the nP-postlabeling assay for alkenylbenzene-DNA
adducts, reversed-phase (C18) TLC is substituted for anion-ex-
change TLC to separate normal DNA nucleotides from adducts.
sample application without drying of the origin area.
Conditions for the various developments have been in-
dicated in the legend of Figure 3. This procedure has
been applied successfully to aromatic carcinogens hav-
ingtwotosix aromatic rings; inthe case ofless aromatic
carcinogens (such as alkenylbenzenes, sterigmatocys-
tin, and aflatoxin B1), removal of normal nucleotides
from the adducts was best accomplished by C18 re-
versed-phase TLC (see Fig. 4).
The lower limit of adduct detection was found to be
1 adduct in (3.5-6) x 107 nucleotides for the standard
4-D PEI-cellulose TLC procedure, while one adduct in
about 105 nucleotides could be detected if removal of
normalnucleotides fromthe adductnucleotides was car-
ried out by reversed-phase TLC, the increase in sen-
sitivity being due to reduced background radioactivity
(6). The technique entails the simultaneous labeling of
60POSTLABELING TEST FOR CARCINOGEN-DNA ADDUCTS
normal and adduct nucleotides, thereby enabling the
accurate quantitation of DNA adduct levels. It is also
possible to isolate the adducts first and then label them
inthe virtualabsence ofnormalnucleotides, atechnique
thataffords anincrease in sensitivity ofdetection to one
adduct in about 1010 normal nucleotides (K. Randerath
and E. Randerath, manuscript submitted).
Some examples of applications of the postlabeling
method follow; additional examples have been described
(4-6). The method was applied to skin DNA from mice
treated topically with the polycyclic aromatic hydro-
carbons benzo(a)pyrene (BP), 7,12-dimethylbenz(a)-
anthracene (DMBA), and 3-methylcholanthrene (MC), re-
spectively. As shown by autoradiography (Fig. 5), a
large number of32P-labeled MC-DNA adducts was de-
tected in digests of DNA obtained from mouse skin at
several time points after carcinogen treatment. Four of
these adducts (spots 4, 7, 9, and 10) were highly per-
sistent (Figs. 5c, 5d). As shown in Figure 6, substantial
removal ofMC-DNA adducts occurred during the first
2 weeks after carcinogen application, while adducts re-
maining thereafter underwent little change. Analogous
results were reported for BP-DNA and DMBA-DNA
adducts (5), with some adducts persisting in mouse ep-
idermis and dermis forabout 1 yearafterasingle topical
carcinogen application (7). These results raise the pos-
sibility that the persistent adducts occupy specific gen-
omic sites in quiescent cells where they may not be
amenable to repair because of localized conformational
alterations ofDNA or shielding by associated proteins.
In Figure 7, application ofthe 3P-postlabeling method
to rat liver DNA after exposure in vivo to the myco-
toxins aflatoxin B, and sterigmatocystin, respectively,
is illustrated. These compounds are known potent he-
patocarcinogens (8,9), and in vivo DNA binding of af-
latoxin B1 has been studied extensively (10,11), but no
such data were available for sterigmatocystin-DNA
binding in vivo. Our studies on these mycotoxins re-
vealed that the adducts seen on32P-labeled fingerprints
(Fig. 7) were mostly oligo- (di- and tri-)nucleotides, be-
cause the enzymatic digestion under standard condi-
tions (4) of DNA containing such adducts led to the
formation of oligonucleotides (mostly di- and trinucleo-
tides) rather than to the formation of the usual mon-
onucleotide adducts (12). Sterigmatocystin-DNA
adducts were detectable in rat liver DNA as late as 3.5
6 14
Days after treatment
FIGURE 5. Maps of32P-labeled digests ofmouse skin DNA isolated
at (a) 1 day, (b) 6 days, (c) 14 days, and (d) 28 days after topical
application offour 1.2-,umole doses of3-methylcholanthrene in 200
,uL acetone each. Digest of DNA from control mice that had re-
ceived acetone only did not give any ofthe numbered spots. Sep-
aration was by the standard procedure (Fig. 3), and spots were
visualized by autoradiography.
FIGURE 6. Time course of relative adduct labeling observed in the
experiment illustrated in Fig. 5. A RAL value of10' corresponds
to a level of 3 fmole adduct/,ug of DNA. Assays were performed
by Cerenkov counting of excised spots. Relative standard devia-
tions were < + 15%.
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FIGURE 7. PEI-cellulosethin-layer mapsof(a,b)aflatoxin B1(AFB,)-
DNA and (c,d) sterigmatocystin (ST)-DNA adducts; (a, b, d) ob-
tained from DNA modified in vivo; (c) from DNA modified in vitro
with sterigmatocystin in the presence of m-chloroperoxybenzoic
acid under conditions similar to those used by Martin and Garner
(11) for chemical modification of DNA with aflatoxin Bl. For the
in vivo samples, rat liver DNA was isolated 2 hr after IP injection
ofthe indicated dose of carcinogen, dissolved in 0.2 mL dimethyl
sulfoxide. Adduct purification was by C18 reversed-phase TLC.
Final mapping was by two-dimensional PEI-cellulose TLC in 3
M ammonium formate (pH 3.5) and 1.15 M Tris-HCl (pH 8.0).
months after injection of a single dose (9 mg/kg) of ster-
igmatocystin to male Fischer rats (12). When equal doses
were compared, sterigmatocystin led to an approxi-
mately 10 times lower level of DNA modification than
did aflatoxin B1, in accord with a close to 10-fold lower
carcinogenic potency of the former compound as com-
pared to the latter (9).
We have applied the 32P-postlabeling test to the an-
alysis ofthe binding of a series ofcarcinogenic and non-
carcinogenic alkenylbenzenes (13) to adult (14) and
newborn (15) mouse liver DNA. Extensive carcinogen-
icity studies by Miller et al. (13) in mice had shownthat,
among these compounds, only three, i.e., safrole, es-
tragole, andmethyleugenol, were hepatocarcinogenic in
the test animals. We wished to ascertain by 32P-postla-
beling assay whether a correlation existed between the
DNA-binding activities of these compounds in mouse
liver and their biological activity or lack of activity in
assays for carcinogenicity in this organ. As illustrated
in Figure 8, our results showed that the known hepa-
tocarcinogens exhibited the strongest binding to mouse
liver DNA 24 hr after IP administration of a 10-mg dose
(one adduct in 10,000-15,000 DNA nucleotides or 200-
300 fmole adduct/,g DNA), while the otherstructurally
related alkenylbenzenes, except eugenol, all bound to
mouse liver DNA also. but at lower levels.
In Table 1, most of the compounds we have studied
thus far are listed, together with the tissues investi-
gated, the number of adducts detected for each com-
pound, and an estimation of total adduct level for each
compound. With the exception of anthracene, pyrene,
and perylene, allthe compounds gave rise to 32P-labeled
adducts at the levels indicated. It appears noteworthy
that within the group of polycyclic aromatic hydrocar-
bons, a good correlation was observed between the car-
cinogenic potency of individual compounds for mouse
skin (16,17) andtheirbindinglevels tomouse skin DNA.
In particular, we failed to detect DNA binding of the
noncarcinogens anthracene, pyrene, and perylene (at a
sensitivity of detection of one adduct in about 109 nu-
cleotides), while the strong carcinogens BP, DMBA,
and MC, exhibited the highest levels of DNA binding.
The illustrations provided in this article and else-
where (4-6) demonstrate that each compound gives rise
to a characteristic fingerprint of 32P-labeled adduct de-
rivatives on PEI-cellulose maps. Therefore, it is pos-
sible on the basis of such fingerprints, to identify the
carcinogen to which the particular DNA had been ex-
posed in vivo.
The adduct intensification version of the 32P-postla-
beling method was recently applied to detect adducts
in human DNA from oralmucosa (B. Dunn, H. F. Stich,
H. P. Agrawal, E. Randerath and K. Randerath, un-
published experiments) and human placenta (E. Ran-
derath, R. Everson, R. Santella and K. Randerath,
unpublished experiments) ofsmokers. This work showed
that the method was applicable to the detection of ad-
ducts in DNA from humans and may thus become a tool
for the detection of genetic damage in cells and tissues
from humans exposed to carcinogenic/mutagenic
chemicals.
Discussion
In this article a recently developed 32P-postlabeling
method for the analysis of carcinogen-nucleic acid ad-
ducts has been reviewed. While we have focused mainly
ontheanalysisofcarcinogen-DNAadducts, themethod
is also applicable to carcinogen-RNA adducts. The sa-
lient features of the new 32P-postlabeling test for cov-
alent DNA binding of chemicals can be summarized as
follows.
The method enables the detection ofminute amounts
of adducts formed by the reaction of DNA with non-
radioactive chemicals. At least in principle, therefore,
DNA binding of any chemical can be assayed.
Since radioactive test chemicals are not required for
in vivo studies, the assay is less expensive than assays
employing radioactive chemicals.
It is applicable to individual compounds and to
mixtures.
The chemical identity of test compounds and/or ad-
62POSTLABELING TEST FOR CARCINOGEN-DNA ADDUCTS
a.Control
.... I-......... :: .".. -... ...}:i
d Dill opiol e.
AnI.OthlO k.Allylb.nzene
FIGURE 8. Maps of 32P-labeled alkenylbenzene-DNA adducts from the livers of female CD-1 mice treated with a single 10-mg dose of the indicated test chemicals in tricaprylin for 24 hr. The adducts were purified by reversed-phase TLC (Fig. 4), resolved by PEI-cellulose anion-exchange TLC, and detected by autoradiography. Control (a), autoradiogram from liver DNA of mice treated with tricaprylin only. Spots of3P-labeled 3',5'-bisphosphates ofadducted deoxyribonucleosides are numbered 1, 2, and 3. X, unknown adduct. Autoradiography at -80° was performed for 12-15 hr, except for anethole (30 hr) and allylbenzene (20 hr) (14).
ducts does not have to be known for DNA binding to
be detected.
Ifthe fingerprint patterns obtained with pure chem-
icals or mixtures are known, then such fingerprints en-
abletheidentification ofthebindingchemical ormixture
to which the DNA had been originally exposed.
Small (microgram) amounts of DNA are required for
analysis.
Themethod ishighlysensitive, inthe case ofaromatic
adducts enabling the detection of a few adducts per
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mammalian genome in a cell population or a tissue.
It can be used for accurate quantitation.
It is potentially useful for investigating the repair,
removal, and loss of adducts from cell or tissue DNA;
the effects ofanticarcinogens, chemopreventive agents,
and/ormetabolicinhibitors onadductformation andper-
sistence can also be studied.
The method appears applicable to DNA from humans
exposed to gene-altering chemicals and thus constitutes
atoolformonitoringhumanexposuretosuchcompounds.
The results reviewed in this article and by others (18)
suggest that chemicals that are capable of forming co-
valent bonds with DNA in mammalian tissues are likely
to be carcinogenic. In combination with chronic bioas-
says forcarcinogenicity, the 32P-postlabeling assay may
thus be useful for answeringthe question as to whether
covalent bond formation between a chemical and DNA
in vivo, by itself, indicates carcinogenic potential ofthe
particular chemical. More test chemicals need to be in-
vestigated to give a definite answer to this important
question.
Included in our analyses were several compounds that,
thoughbeingstructurallyrelatedtoknowncarcinogens,
have notbeenfound todate to be carcinogenic inchronic
animal bioassays, i.e., 4-acetylaminofluorene, anthra-
cene, pyrene, perylene, myristicin, dill apiol, parsley
apiol, elemicin, anethole, and allylbenzene. With the
exception of the polycyclic aromatic hydrocarbons, an-
thracene, pyrene, and perylene, DNA binding ofthese
compounds in vivo was detected by 32P-postlabeling as-
say, but was found to occurto amuch lesser extent than
that of the structurally related carcinogens. For ex-
ample, the binding to rat liver DNA of 4-acetylamino-
fluorene was below that of 2-acetylaminofluorene by a
factor ofabout 400 fold, and the noncarcinogenic alken-
ylbenzenes [myristicin, dill apiol, parsley apiol, elemi-
cin, anethole, and allylbenzene (13)] bound to mouse
liver DNA 4 to 200 times less than their carcinogenic
counterparts (safrole, estragole, and methyleugenol) (14)
Theseresultsdemonstrate thatthe32P-postlabelingtest
is capable of detecting weakly genotoxic compounds,
which either are not carcinogenic or whose carcinogen-
icity is not readily shown in animal bioassays. A com-
pound such as myristicin, which binds only ca. 4 fold
less than the structurally related hepatocarcinogen saf-
role to mouse liver DNA (14), but has not been shown
to induce cancer in mouse bioassays (13), was found to
exhibit substantial genotoxic activity in mouse liver in
vivo. This raises the question as to whether the com-
pound actually lacks any carcinogenic activity in spite
of its DNA-damaging potential or whether bioassays
conducted under different conditions would show its
carcinogenicity.
Ashby (19) has recommended that a substantial pro-
portionofthe resourcescurrentlyearmarkedforchronic
carcinogenicity bioassays might rather be employed in
short-term in vivo evaluations in rodents of chemicals
known to be genotoxic from various in vitro tests. On
the basis of our results, the 32P-postlabeling assay ap-
pears suitable to serve as such a short-term test for the
detection ofcarcinogen-DNA adducts in animal tissues,
i.e., asanassayforpotentialcarcinogenicity ofchemicals.
We have also pointed out in this article that the 32P-
postlabeling technique represents a tool to assay an im-
portant property of chemical carcinogens, i.e., the for-
mation of persistent DNA adducts, which may play a
crucial role in carcinogenesis. In using the test for the
detection ofcovalent binding ofchemicals to DNA, one
should therefore also include an evaluation of adduct
persistence. Compounds such as 7,12-dimethyl-
benz(a)anthracene or sterigmatocystin, which give rise
inanimals to highly persistent, essentially nonreparable
adducts, induce irreversible toxic effects in the genetic
material of mammals in vivo; it would appear prudent
to preclude or minimize human exposure to such chem-
icals by appropriate regulatory measures. Since the32P-
postlabeling assay makes possible the detection and
quantitation of covalent binding of chemicals to DNA,
as well as an analysis ofthe persistence ofDNA lesions,
it may become an important tool for risk assessment of
genotoxic chemicals.
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